Geneesmiddelen | Horizonscan geneesmiddelen

Lisdexamfetamine ^IND Molindone

autologous anti-CD19-transduced CD3+ cells ^IND

Blinatumomab

Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. ^IND Extension of indication to include the use of blinatumomab as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as consolidation therapy ^IND

Dasatinib

Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. ^G Geïndiceerd voor de behandeling van volwassen patiënten met: nieuw gediagnosticeerde Philadelphiachromosoom-positieve (Ph+) chronische myeloïde leukemie (CML) in de chronische fase. CML in de chronische, acceleratie- of blastaire fase, die resistent of intolerant zijn voor eerder toegediende geneesmiddelen inclusief imatinib. Ph+ acute lymfoblastaire leukemie (ALL) en lymfoïde blasten CML die resistent of intolerant zijn voor eerder toegediende geneesmiddelen. Ook geïndiceerd voor de behandeling van pediatrische patiënten met: nieuw gediagnosticeerde Ph+ CML in de chronische fase (Ph+ CML-CP) of met Ph+ CML-CP die resistent of intolerant zijn voor eerder toegediende geneesmiddelen waaronder imatinib. Nieuw gediagnosticeerde Ph+ ALL in combinatie met chemotherapie. ^G

Arimoclomol

Arseentrioxide

Geïndiceerd voor het induceren van remissie en consolidatie bij volwassen patiënten met: 1) nieuw gediagnosticeerde acute promyelocytaire leukemie (APL) met laag tot middelmatig risico (aantal witte bloedcellen ≤ 10 x 103/μl) in combinatie met all-trans-retinoïnezuur (ATRA), 2) recidiverende/refractaire acute promyelocytaire leukemie (APL) (tijdens een eerdere behandeling moet een retinoïde stof zijn toegediend en chemotherapie hebben plaatsgehad), gekenmerkt door de aanwezigheid van de translocatie t(15;17) en/of de aanwezigheid van het gen promyeolocitaire-leukemie-/retinoïnezuurreceptor-alfa (PML/RAR-alfa). ^G Geïndiceerd voor het induceren van remissie en consolidatie bij volwassen patiënten met: 1) nieuw gediagnosticeerde acute promyelocytaire leukemie (APL) met laag tot middelmatig risico (aantal witte bloedcellen ≤ 10 x 103/μl) in combinatie met all-trans-retinoïnezuur (ATRA), 2) recidiverende/refractaire acute promyelocytaire leukemie (APL) (tijdens een eerdere behandeling moet een retinoïde stof zijn toegediend en chemotherapie hebben plaatsgehad), gekenmerkt door de aanwezigheid van de translocatie t(15;17) en/of de aanwezigheid van het gen promyeolocitaire-leukemie-/retinoïnezuurreceptor-alfa (PML/RAR-alfa). ^G Geïndiceerd voor het induceren van remissie en consolidatie bij volwassen patiënten met: 1) nieuw gediagnosticeerde acute promyelocytaire leukemie (APL) met laag tot middelmatig risico (aantal witte bloedcellen ≤ 10 x 103/μl) in combinatie met all-trans-retinoïnezuur (ATRA), 2) recidiverende/refractaire acute promyelocytaire leukemie (APL) (tijdens een eerdere behandeling moet een retinoïde stof zijn toegediend en chemotherapie hebben plaatsgehad), gekenmerkt door de aanwezigheid van de translocatie t(15;17) en/of de aanwezigheid van het gen promyeolocitaire-leukemie-/retinoïnezuurreceptor-alfa (PML/RAR-alfa). ^G

Azacitidine

AML post-intensive chemotherapy maintenance therapy for patients in complete remission Geïndiceerd voor de behandeling van volwassen patiënten die niet in aanmerking komen voor hematopoëtische stamceltransplantatie (HSCT), met: • intermediair 2 en hoog risico myelodysplastische syndromen (MDS) volgens het International Prognostic Scoring System (IPSS), • chronische myelomonocytaire leukemie (CMML) met 10%-29% beenmergblasten zonder myeloproliferatieve aandoening, • acute myeloïde leukemie (AML) met 20%-30% blasten en multilineaire dysplasie, volgens de indeling van de Wereldgezondheidsorganisatie (WHO). • AML met >30% beenmergblasten volgens de indeling van de WHO. ^G Geïndiceerd voor de behandeling van volwassen patiënten die niet in aanmerking komen voor hematopoëtische stamceltransplantatie (HSCT), met: • intermediair 2 en hoog risico myelodysplastische syndromen (MDS) volgens het International Prognostic Scoring System (IPSS), • chronische myelomonocytaire leukemie (CMML) met 10%-29% beenmergblasten zonder myeloproliferatieve aandoening, • acute myeloïde leukemie (AML) met 20%-30% blasten en multilineaire dysplasie, volgens de indeling van de Wereldgezondheidsorganisatie (WHO). • AML met >30% beenmergblasten volgens de indeling van de WHO. ^G Geïndiceerd voor de behandeling van volwassen patiënten die niet in aanmerking komen voor hematopoëtische stamceltransplantatie (HSCT), met: • intermediair 2 en hoog risico myelodysplastische syndromen (MDS) volgens het International Prognostic Scoring System (IPSS), • chronische myelomonocytaire leukemie (CMML) met 10%-29% beenmergblasten zonder myeloproliferatieve aandoening, • acute myeloïde leukemie (AML) met 20%-30% blasten en multilineaire dysplasie, volgens de indeling van de Wereldgezondheidsorganisatie (WHO). • AML met >30% beenmergblasten volgens de indeling van de WHO. ^G

Gilteritinib Glasdegib Guadecitabine Idasanutlin Imetelstat Iomab-B

Ivosidenib

Relapsed or refractory isocitrate dehydrogenase-1 (IDH-1) mutation-positive acute myeloid leukaemia Acute myeloid leukaemia (AML), isocitrate dehydrogenase-1 (IDH1) mutation - first-line combination therapy. ^IND

Luspatercept Sapacitabine Venetoclax ^IND

Brentuximab vedotin ^IND Lisocabtagene maraleucel Polatuzumab vedotin Rituximab ^IND Tafasitamab Tagraxofusp Zanubrutinib

Arachis hypogaea (pinda) allergenen (capsule) Arachis hypogaea (pinda) allergenen (pleister) Olopatadine / mometasone Omalizumab ^IND

Apixaban ^G Dabigatran ^G Dabigatran etexilate ^IND Ravulizumab ^IND Rivaroxaban ^IND

Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium ^IND Budesonide / formoterol ^IND Fluticasone furoate / umeclidinium / vilanterol ^IND Indacaterol acetate/glycopyrronium bromide/mometasone furoate Indacaterol acetate/mometasone furoate Masitinib ^IND

Omalizumab

Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. ^BS Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. ^BS Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma. Ook voor de behandeling van chronische idiopathische urticaria. ^BS

Amoxicilline / omeprazol / rifabutin Cefiderocol

Ceftaroline fosamil

Indicatie uitbreiding voor de behandeling van kinderen jonger dan twee maanden voor gecompliceerde infecties van de huid en van de weke delen (Complicated Skin and Soft Tissue Infection, cSSTI) en buiten het ziekenhuis opgelopen pneumonie (Community-acquired pneumonia, CAP). ^IND Extension of indication for the treatment of community acquired pneumonia (CAP) to include concurrent bacteraemia due to Streptococcus pneumoniae (SP) for all age groups. ^IND

Ceftazidime / avibactam

Zavicefta is indicated in adults and children aged 3 months and older and adolescents for the treatment of the following infections in adults with Complicated intra-abdominal infection (cIAI), Complicated urinary tract infection (cUTI), including pyelonephritis, Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP). ^IND Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, the currently approved indications for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired pneumonia, including ventilator-associated pneumonia. ^IND

Ceftolozaan / tazobactam ^IND

Delafloxacin

Quofenix is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Extension of indication to include treatment of Community Acquired Pneumonia (CAP) for Quofenix 450 mg tablets and 300 mg powder for concentrate for solution for infusion. ^IND

Delamanid ^IND Iclaprim

Imipenem / cilastatin / relebactam

Recarbrio is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults. Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults. ^IND

Lefamulin Liposomaal amikacine Obiltoxaximab Ozenoxacine Plazomicin Pretomanid

Tedizolid

Hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), complex bacterial infections, caused by gram positive pathogens ^IND Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older. ^IND

Tigecycline ^G

Lumateperone Lurasidone ^IND

Atezolizumab

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC), after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%. ^IND Adjuvant treatment after surgical resection of high-risk muscle-invasive bladder cancer (MIBC). ^IND

Avelumab ^IND Durvalumab ^IND Enfortumab vedotin Oportuzumab monatox Pembrolizumab ^IND Ramucirumab ^IND Tremelimumab ^IND

Adalimumab ^IND

Alicaforsen

Pouchitis Ulcerative colitis

Filgotinib Remestemcel-L ^IND Tenapanor Upadacitinib ^IND

Asunercept Autologous glioma tumor cell lysates Brain cancer vaccine Tasadenoturev Vocimagene amiretrorepvec

Abemaciclib ^IND Alpelisib

Atezolizumab

Neoadjuvant treatment for patients with early TNBC in combination with nab-paclitaxel. ^IND Treatment of patients with previously untreated metastatic TNBC in combination with paclitaxel. ^IND

Margetuximab Neratinib ^IND Olaparib ^IND Paclitaxel

Palbociclib

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery. ^IND Patients with HR+/HER2- invasive early breast cancer in combination with standard adjuvant endocrine therapy. ^IND

Pembrolizumab

Breast cancer, metastatic, triple negative, 1L. ^IND Tripple Negative Breast Cancer - Neoadjuvant and adjuvant. ^IND

Pertuzumab / trastuzumab Sacituzumab govitecan

Trastuzumab deruxtecan

Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 therapies. Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy ^IND Treatment of adult patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane 2L. ^IND

Trastuzumab duocarmazine

Trastuzumab emtansine

Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. ^IND Trastuzumab entansine in combination with pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer. ^IND

Tucatinib Veliparib

Acalabrutinib

Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Duvelisib

Ibrutinib

Extension of indication to the existing chronic lymphocytic leukaemia (CLL) indication to include combination use with obinutuzumab for the treatment of adult patients with previously untreated CLL. ^IND Extension of indication in chronic lymphocytic leukaemia (CLL) to add combination with rituximab as follows; Ibrutinib in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated CLL (Young and Fit). ^IND

ibrutinib ^IND Moxetumomab pasudotox Ublituximab Venetoclax ^IND

Formoterol / glycopyronium / budesonide Revefenacin

Avacopan Sutimlimab

Eflornithine / sulindac Encorafenib ^IND Tegafur / gimeracil / oteraci ^IND

Bamocaftor / tezacaftor / ivacaftor

Aducanumab

Leuco-methylthioninium

Alzheimer’s disease, mild-to-moderate. Dementia, behavioural variant frontotemporal.

Brexanolone

Esketamine

Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. Extension of indication to include a new indication for Spravato for the rapid reduction of depressive symptoms in adult patients with a moderate to severe depressive episode of MDD who have current suicidal ideation with intent. ^IND

Zuranolone

Canagliflozine ^IND Canagliflozine / metformine ^IND Dapagliflozin / saxagliptin / metformin

Dapagliflozine

Extension of Indication to include type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. ^IND Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old ^IND

Dasiglucagon Empagliflozine ^IND Exenatide Finerenone Glucagon

Insulin aspart

The treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. ^BS The treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. ^BS

Insulin lispro (ultra rapid formulation) Polyethylene glycol loxenatide Reparixin Semaglutide

Sotagliflozine

Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy. Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control ^IND

Teplizumab Tirzepatide

Edasalonexent

Idebenone

Treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) NOT using glucocorticoids. Respiratory dysfunction is defined when PEF%p or FVC%p fall below 80% of the predicted value Treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) using glucocorticoids. Respiratory dysfunction is defined when PEF%p or FVC%p fall below 80% of the predicted value ^IND

Cannabidiol

Indicated for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older. Extension of indication for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 1 year of age and older. ^IND

Cenobamate

Fenfluramine

Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome ^IND

Perampanel ^IND

Abicipar Aflibercept ^BS Aganirsen Brolucizumab ^IND Faricimab Latanoprostene bunod Lenadogene nolparvovec Lifitegrast Netarsudil / latanoprost Polihexanide

Ranibizumab

Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Treatment of neovascular age-related macular degeneration (AMD)

Reproxalap Sepofarsen Timrepigene emparvovec Tivanisiran Voretigene neparvovec

Afatinib ^IND Brilacidin

Durvalumab

Squamous cell carcinoma of the head and neck, 1L PDL 1 in combination with tremelimumab ^IND Squamous cell carcinoma of the head and neck, 1L PDL 1. ^IND

Leukocyte interleukin Pembrolizumab ^IND

Eptinezumab Erenumab Fremanezumab Galcanezumab Lasmiditan

Brimapitide Pioglitazone

Carmustine ^G

Emicizumab ^IND Eptacog beta (activated) Etranacogene dezaparvovec Fibrinogen Fidanacogene elaparvovec Valoctocogene roxaparvovec

Pembrolizumab ^IND

Levoketoconazole Linzagolix Lonapegsomatropin Macimorelin Octreotide Osilodrostat

Relugolix

Patients With Endometriosis-Associated Pain ^IND Treatment of uterine fibroids.

Somapacitan Somatrogon Tenapanor ^IND

Axicabtagene ciloleucel ^IND Copanlisib

Ibrutinib

Follicular lymphoma (FL), relapsed / refractory. ^IND Marginal zone lymphoma (MZL), relapsed / refractory. ^IND

Umbralisib

Avelumab ^IND Cabozantinib ^IND Ipilimumab ^IND

Pembrolizumab

Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy. ^IND Advanced Renal Cell Carcinoma (1L) in combination with lenvatinib. ^IND

Tivozanib ^IND

Asciminib

Bempedoic acid Bempedoic acid / ezetimibe Evinacumab Inclisiran Volanesorsen

Atezolizumab ^IND Pembrolizumab ^IND Pemigatinib

Givosiran Maralixibat Obeticholic acid ^IND Odevixibat Seladelpar

Amivantimab

Atezolizumab

For the 1L treatment of patients with metastatic, squamous NSCLC in combination with chemotherapy. ^IND Extension of indication to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1. ^IND

Avelumab ^IND

Brigatinib

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. ^IND Geïndiceerd voor gebruik als monotherapie voor de behandeling van volwassen patiënten met ALK‑positief (anaplastisch lymfoom kinase) gevorderd niet‑kleincellig longcarcinoom (NSCLC) die eerder zijn behandeld met alectinib. ^IND

Canakinumab ^IND Cemiplimab ^IND Dacomitinib

Durvalumab

Non-small cell lung cancer (NSCLC) stage IV, in combination with tremelimumab and chemo,1L. Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. ^IND Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND

Entrectinib Lurbinectedin Mobocertinib

Nivolumab

Extension of Indication to include first-line treatment of adult patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC) in combination with ipilimumab and two cycles of chemotherapy. ^IND Opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation. ^IND

Osimertinib ^IND

Pembrolizumab

Extension of Indication to include 1st line treatment of locally advanced or metastatic non-small cell lung cancer tumours expressing PD-L1 with a ≥ 1% tumour proportion score (TPS). ^IND Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the treatmen of extensive stage Small Cell Lung Cancer (SCLC) (1L). ^IND

Pralsetinib Selpercatinib Sotorasib Tepotinib Trilaciclib

Nivolumab ^IND

Arimoclomol citraat Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene Avalglucosidase alfa Burosumab ^IND Chenodeoxycholzuur Elivaldogene autotemcel Hydrocortisone Kaliumcitraat / kaliumwaterstofcarbonaat Lonafarnib Nitisinone ^IND Olipudase alfa Pegvaliase Reloxaliase Trientine Vestronidase alfa Veverimer Volanesorsen ^IND

Belantamab mafodotin Carfilzomib ^IND

Daratumumab

Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). ^IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). ^IND Amyloidose eerstelijnsbehandeling in combinatie met bortezomib, cyclofosfamide en dexamethason. ^IND In combinatie met pomalidomide en dexamethason voor patiënten met multipel myeloom die tenminste een eerdere lijn van behandeling hebben gehad. ^IND Subcutaneous formulation indicates for Relapsed or Refractory Multiple Myeloma. ^IND Multipel myeloom frontline behandeling i.c.m. VRd voor patiënten die niet in aanmerking komen voor een ASCT. ^IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die in aanmerking komen voor een ASCT. ^IND Multipel myeloom frontline onderhoudsbehandeling na DVTd, voor patiënten die in aanmerking komen voor een ASCT. ^IND Smouldering multipel myeloom. ^IND

Ibrutinib ^IND Idecabtagene vicleucel

Isatuximab

Sarclisa is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy. Combinatie van isatuximab met carfilzomib en dexamethason bij patiënten met gerecidiveerd en refractair multipel myeloom na 1 tot maximaal 3 eerdere behandellijnen. ^IND

JNJ-4528 Lenalidomide ^IND Pomalidomide ^IND Selinexor Zanubrutinib

Fampridine ^G Fingolimod ^G Masitinib Natalizumab Ofatumumab Ozanimod Ponesimod Siponimod Teriflunomide ^IND

Sugammadex ^G

Fedratinib Ropeginterferon alfa-2b

Selumetinib Surufatinib

Anakinra ^IND Belatacept ^IND Belimumab ^IND Berotralstat Elobixibat Emapalumab Forigerimod Icatibant ^G Imlifidase Lanadelumab Naldemedine RP-L201 Teprasiran Teprotumumab Triamcinolone Voclosporin

Anidulafungin ^IND Ibrexafungerp ^IND

Posaconazol

Rezafungin

Ambrisentan ^G Benralizumab ^IND Gefapixant

Mepolizumab

Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala ^IND Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). ^IND

Molgramostim

Nintedanib

Ofev is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease. ^IND Ofev is indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype. ^IND

Omalizumab ^IND Sarizotan

Allogenic immunomodulatory progenitor cells Angiotensin II Apabetalon

Dapagliflozine

Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. ^IND Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) ^IND

Emiplacel

Empagliflozine

Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). ^IND Extension of indication to include treatment of adult patients with heart failure and reduced ejection fraction for Jardiance ^IND

Icosapent ethyl Regadenoson ^IND Tafamidis ^IND

Ticagrelor

Extension of indication to include, in co administration with acetylsalicylic acid (ASA), the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) without a history of myocardial infarction who have undergone percutaneous coronary intervention (PCI). ^IND Extension of indication to include, in co-administration with acetylsalicylic acid (ASA), the prevention of stroke in adult patients with acute ischaemic stroke or transient ischaemic attack (TIA) in the previous 24 hours. ^IND

Treprostinil Udenafil Valsartan / sacubitril ^IND Vericiguat

Autologous human chondrocytes in vitro expanded Dapagliflozine ^IND Elamipretide Fexapotide Liraglutide ^IND Lumasiran Nolasiban Romosozumab Semaglutide ^IND Setmelanotide ^IND Vosoritide

AMDC-USR Mexiletine HCl

Buprenorphine Eculizumab ^IND Eladocagene exuparvovec Inebilizumab Remimazolam Ronopterin Satralizumab

Avatrombopag

Betibeglogene autotemcel

Zynteglo is geïndiceerd voor gebruik bij patiënten in de leeftijd van 12 jaar en ouder met transfusie-afhankelijke β-thalassemie (transfusion-dependent β-thalassaemia - TDT) die geen β0/β0-genotype hebben, voor wie transplantatie van hematopoëtische stamcellen (HSC) gepast is, maar geen humaan leukocytenantigeen (HLA)-compatibele gerelateerde HSC-donor beschikbaar is. Behandeling van patiënten jonger dan 12 jaar met transfusie-afhankelijke β-thalassemie (TDT) die geen β0/β0-genotype hebben en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is. ^IND Behandeling van patiënten met transfusie-afhankelijke β-thalassemie (TDT) die een β0 mutatie op beide allelen van het β-globuline (HBB) hebben, en voor wie hematopoïetische stamceltransplantatie (HSC) gepast is, maar voor wie geen humaan leukocyt antigeen (HLA)-compatibele verwante HSC-donor beschikbaar is ^IND

Crizanlizumab Daprodustat

Deferasirox

Eculizumab

Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). ^BS

Ferumoxytol

Hydroxycarbamide

Geïndiceerd voor de preventie van recidiverende, pijnlijke vaso-occlusieve crises waaronder het 'acute chest syndrome' bij volwassenen, adolescenten en kinderen ouder dan 2 jaar met symptomatische sikkelcelziekte. ^G Extension of indication to include treatment of severe chronic anemia (haemoglobin level < 6 g/dL or < 7 g/dL with poor clinical or functional tolerance) in adults, adolescents and children older than 2 years suffering from sickle cell syndrome. ^IND

Luspatercept Mepolizumab ^IND Pegcetacoplan Ravulizumab Romiplostim ^IND Roxadustat RP-L102 Thrombomodulin alfa Vadadustat Voxelotor

131I-omburtamab Dostarlimab Entrectinib Glucarpidase Ivosidenib ^IND Larotrectinib Lipegfilgrastim ^IND Nivolumab ^IND

Pembrolizumab

Extension of indication to include first-line treatment of unresectable or metastatic microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults for Keytruda. ^IND Advanced Endometrial Cancer (2L+) in combination with lenvatinib. ^IND Locally advanced or metastatic esophageal carcinoma (1L) ^IND Women With Persistent, Recurrent, or Metastatic Cervical Cancer (1L). ^IND

Pexidartinib Sodium thiosulfate

Atezolizumab ^IND Niraparib ^IND Olaparib ^IND Veliparib

Bupivacaine Bupivacaine / meloxicam Lidocaïne Neridronic Acid

Tanezumab

Treatment of moderate to severe chronic pain associated with OA of the hip or knee in adult patients for whom treatment with NSAIDs and/or any opioid is ineffective, not tolerated or inappropriate Chronic Low Back Pain for ≥3 months ^IND

Eryaspase (Asparaginase) Olaparib ^IND

Amantadine Apomorphine Istradefylline Levodopa / carbidopa Pimavanserin

Abiraterone

Abiraterone / apalutamide Apalutamide ^IND Cabazitaxel ^G

Darolutamide

Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT. ^IND

DCVAC

Enzalutamide

Adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. ^IND De behandeling van volwassen mannen met niet-gemetastaseerd hoog risico-CRPC (castratieresistent prostaatcarcinoom). ^IND

Niraparib ^IND Olaparib ^IND Relugolix

Anifrolumab Filgotinib Guselkumab ^IND Ixekizumab ^IND Olokizumab Secukinumab ^IND Tocilizumab ^BS

Tofacitinib

Treatment of active polyarticular course juvenile idiopathic arthritis patients 2 years of age and older. ^IND Ankylosing Spondylitis ^IND

Upadacitinib

Extension of indication to include the treatment of active ankylosing spondylitis in adult patient for Rinvoq ^IND RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who haveresponded inadequately to, or who are intolerant to one or more DMARD. RINVOQ may be used as monotherapy or in combination with nonbiologic DMARDs. ^IND

Ustekinumab ^IND

Onasemnogene abeparvovec Risdiplam

Lurasidone ^IND Olanzapine / samidorphan

Atezolizumab ^IND

Cemiplimab

Monotherapy treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Libtayo wordt onderzocht in patiënten met gevorderd basaalcelcarcinoom van de huid (cBCC) die progressie vertonen onder behandeling met hedgehog inhibitor therapie of intolerant waren voor eerdere behandeling met hedgehog inhibitor therapie. ^IND

Dabrafenib / Trametinib ^IND Darleukin fibromun Lifileucel Relatlimab Seviprotimut-L Spartalizumab Tavokinogene telseplasmid

Abrocitinib Baricitinib ^IND Beremagene geperpavec Berkenschorsextract ^IND Bimekizumab Clascoterone Crisaborole Difelikefalin Dupilumab ^IND Glycopyrronium tosylate Ixekizumab ^IND Lebrikizumab Nemolizumab Secukinumab ^IND

Tapinarof

Adult Plaque Psoriasis Atopische dermatitis

Tirbanibulin Tralokinumab Trifarotene Upadacitinib ^IND

JZP-258 Lemborexant Natriumoxybaat ^IND Solriamfetol Tasimelteon ^IND

autologous anti-CD19-transduced CD3+ cells Axicabtagene ciloleucel ^IND BL-8040 Ibrutinib ^IND Inolimomab Itacitinib Narsoplimab Omidubicel Remestemcel-L Rimiducid Rivogenlecleucel Ruxolitinib ^IND Tabelecleucel Thiotepa ^G

Avapritinib Masitinib Ripretinib Rivoceranib Trastuzumab deruxtecan ^IND

Selpercatinib

Patients With RET-Mutant Medullary Thyroid Cancer. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Vibegron

APN01 Atazanavir / cobicistat Baloxavir marboxil Bulevirtide Cabotegravir Dapagliflozine ^IND Dexamethasone ^IND Etravirine ^IND Fostemsavir Glecaprevir / pibrentasvir ^IND Human normal immunoglobulin ^IND Ibalizumab Maribavir Remdesivir Tecovirimat Zanamivir

Informatie over geneesmiddelen die in de nabije toekomst op de markt verwacht worden.

Published on 8 December 2020

ADHD

ALL

Blinatumomab

Dasatinib

ALS

AML / MDS

Arseentrioxide

Azacitidine

Ivosidenib

Aggressive non-Hodgkin's lymphoma

Allergy

Antithrombotic medications

Asthma

Omalizumab

Bacterial infections

Ceftaroline fosamil

Ceftazidime / avibactam

Delafloxacin

Imipenem / cilastatin / relebactam

Tedizolid

Bipolar disorder

Bladder cancer

Atezolizumab

Bowel diseases

Alicaforsen

Brain cancer

Breast cancer

Atezolizumab

Palbociclib

Pembrolizumab

Trastuzumab deruxtecan

Trastuzumab emtansine

CLL

Acalabrutinib

Ibrutinib

COPD

Cardiovascular diseases

Colon cancer

Cystic fibrosis

Elexacaftor / tezacaftor / ivacaftor

Ivacaftor

Tezacaftor / ivacaftor

Dementia

Leuco-methylthioninium

Depression

Esketamine

Diabetes

Dapagliflozine

Insulin aspart

Sotagliflozine

Duchenne

Idebenone

Epilepsy

Cannabidiol

Fenfluramine

Eye disorders

Ranibizumab

Head and neck cancer

Durvalumab

Headache

Hearing disorders

Hematology other

Hemostasis promoting medication

Hodgkin's lymphoma

Hormonal disorders

Relugolix

Indolent non-Hodgkin's lymphoma

Ibrutinib

Kidney cancer

Pembrolizumab

Leukemia

Lipid-lowering medications

Liver cancer

Liver diseases

Lung cancer

Atezolizumab

Brigatinib

Durvalumab